Market closedNon-fractional
Ocugen, Inc/OCGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Ocugen, Inc
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Ticker
OCGN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Malvern, United States
Employees
65
Website
www.ocugen.com
Ocugen, Inc Metrics
BasicAdvanced
$419M
Market cap
-
P/E ratio
-$0.23
EPS
3.80
Beta
-
Dividend rate
Price and volume
Market cap
$419M
Beta
3.8
Financial strength
Current ratio
1.869
Quick ratio
1.643
Long term debt to equity
16.348
Total debt to equity
22.577
Management effectiveness
Return on assets (TTM)
-50.40%
Return on equity (TTM)
-108.76%
Valuation
Price to revenue (TTM)
62.235
Price to book
13.88
Price to tangible book (TTM)
13.88
Price to free cash flow (TTM)
-6.266
Growth
Revenue change (TTM)
125.42%
Earnings per share change (TTM)
-41.03%
3-year revenue growth (CAGR)
435.61%
3-year earnings per share growth (CAGR)
-3.51%
What the Analysts think about Ocugen, Inc
Analyst Ratings
Majority rating from 3 analysts.
Ocugen, Inc Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1M
-83.33%
Net income
-$12M
26.60%
Profit margin
-1,190.00%
659.61%
Ocugen, Inc Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.10
-$0.06
-$0.03
-$0.05
-
Expected
-$0.07
-$0.07
-$0.07
-$0.06
-$0.05
Surprise
36.36%
-14.29%
-53.85%
-21.05%
-
Ocugen, Inc News
AllArticlesVideos
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
GlobeNewsWire·2 days ago
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
GlobeNewsWire·1 month ago
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ocugen, Inc stock?
Ocugen, Inc (OCGN) has a market cap of $419M as of July 27, 2024.
What is the P/E ratio for Ocugen, Inc stock?
The price to earnings (P/E) ratio for Ocugen, Inc (OCGN) stock is 0 as of July 27, 2024.
Does Ocugen, Inc stock pay dividends?
No, Ocugen, Inc (OCGN) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Ocugen, Inc dividend payment date?
Ocugen, Inc (OCGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Ocugen, Inc?
Ocugen, Inc (OCGN) has a beta rating of 3.8. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Ocugen, Inc stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.